European urology最新文献

{"title":"Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non–muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.03.018","authors":"Xin Rui, Xiaoming Xu, Bo Dai","doi":"10.1016/j.eururo.2025.05.036","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.036","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"3 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144237341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer","authors":"Peter Albertsen","doi":"10.1016/j.eururo.2025.05.029","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.029","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"18 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144237349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: The Prognostic Value of p53 and Ki-67 Expression Status in Penile Cancer: A Systematic Review and Meta-analysis","authors":"Kaat Vandermaesen, Laura Elst, Xianjie Xiu, Maarten Albersen","doi":"10.1016/j.eururo.2025.05.030","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.030","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"99 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144237348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Socioeconomic, and Environmental Costs of Urinary Incontinence in the European Union","authors":"Chrissy Bishop, Federico Rodriguez-Cairoli, Arnold Hagens, Maria Angela Bermudez, Philip Van Kerrebroeck, Sarah Collen","doi":"10.1016/j.eururo.2025.05.025","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.025","url":null,"abstract":"<h3>Background and objective</h3>Up to 40% of the population suffers from urinary incontinence (UI). UI can be managed through qualified early assessment, possibly reducing associated health care costs. However, limited studies have estimated the economic burden of UI in the European Union (EU). This study estimates the economic burden of UI on individuals, carers, health systems, long-term care, and society in the EU.<h3>Methods</h3>Prevalence data were extracted or estimated to inform the epidemiological burden of UI in the EU. The economic burden of UI in 27 EU member states was then estimated, which included direct and indirect productivity losses and incontinence pad disposal costs. The 2023 results were presented, and projections for 2030 were estimated for future costs if no preventative action is taken. All costs were expressed in euros (EUR€).<h3>Key findings and limitations</h3>In 2023, the EU economic burden of UI was EUR€69.1 billion (EUR€26.1–133.4 billion) without caregiver costs, with females bearing quadruple the burden compared with males. On average, per-patient annual costs were EUR€1,470.6. Caregiver costs increased EU economic burden to EUR€80.0 billion (EUR€32.5–150.6 billion) with per-patient per-year costs increasing to EUR€1,700.0. In 2030, the economic burden could rise to EUR€100.2 billion (EUR€40.8–188.6 billion). Shifting to 100% incontinence pad waste recycling could reduce the overall carbon footprint of continence health in Europe by 117.8 million kg CO2e in 2023.<h3>Conclusions and clinical implications</h3>A high UI economic burden emphasises the economic and environmental benefits of prevention. The results highlight the need for recognising the high economic burden in women, improved prevalence data surveillance driving effective prevention strategies, and formally recognising secondary caregivers in the UI treatment pathway.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"12 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144237342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Yi-Qi Chen, Zhi-Bo Zhou, and Xue-Qin Bai’s Letter to the Editor re: Grant D. Stewart, Angela Godoy, Fiona Farquhar, et al. Abdominal Noncontrast Computed Tomography Scanning To Screen for Kidney Cancer and Other Abdominal Pathology Within Community-based Computed Tomography Screening for Lung Cancer: Results of the Yorkshire Kidney Screening Trial. Eur Urol 2025;87:561–70","authors":"Sabrina H. Rossi, Stewart Manning, Juliet A. Usher-Smith, Grant D. Stewart","doi":"10.1016/j.eururo.2025.05.026","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.026","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"31 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144211270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease","authors":"Joaquim Bellmunt, Thomas Powles, Se Hoon Park, Eric Voog, Begona P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Cora N. Sternberg, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Miguel A. Climent Duran, Karin Tyroller, Jason Hoffman, Natalia Jacob, Petros Grivas, Shilpa Gupta","doi":"10.1016/j.eururo.2025.05.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.017","url":null,"abstract":"In the JAVELIN Bladder 100 randomized phase 3 trial (<em>N</em> = 700), avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) without progression after first-line platinum-based chemotherapy (PBC). Here, we report exploratory analyses of subgroups with nonvisceral metastases at the start of PBC (including bone metastases) or lymph node–only disease at randomization. The median OS with avelumab versus control in patients with nonvisceral metastases (<em>n</em> = 318) was 31.4 versus 17.1 mo (hazard ratio [HR], 0.60 [95% confidence interval {CI}, 0.45–0.79]), and in patients with lymph node–only disease (<em>n</em> = 102), it was 31.9 versus 22.7 mo (HR, 0.86 [95% CI, 0.51–1.47]). In patients with nonvisceral metastases, prolonged OS was observed with avelumab irrespective of the response to PBC or PBC regimen received. PFS analyses favored avelumab over control in all the subgroups. Incidences of avelumab-related adverse events were similar across the subgroups. Limitations include small sample sizes and the exploratory nature of analyses. Overall, exploratory analyses suggest that in first-line PBC-treated patients without progression, avelumab maintenance is effective and has a manageable toxicity profile in patients with aUC who have nonvisceral metastases or lymph node–only disease.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"20 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144211269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging–targeted Biopsy in the PROBASE Trial","authors":"Rouvier Al-Monajjed, Matthias Boschheidgen, Jale Lakes, Agne Krilaviciute, Jan-Philipp Radtke, Heinz-Peter Schlemmer, David Bonekamp, Kathleen Herkommer, Matthias Jahnen, Jürgen E. Gschwend, Daniel Düx, Frank Wacker, Marcus R. Makowski, Andreas Sauter, Markus A. Kuczyk, Nina Harke, Jürgen Debus, Christoph Grott, Christian Arsov, Petra Seibold, Peter Albers","doi":"10.1016/j.eururo.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.020","url":null,"abstract":"The optimal approach for prostate cancer (PC) screening, including the ideal starting age and most effective diagnostic method, remains under investigation. We evaluated the diagnostic performance of magnetic resonance imaging (MRI)-targeted biopsy (TBx) and systematic biopsy (SBx) in detecting clinically significant PC (csPC) in men aged 45–50 yr in PROBASE, a prospective, randomized trial of a risk-adapted screening strategy. A total of 525 participants with elevated prostate-specific antigen (≥3 ng/ml) underwent MRI followed by biopsy. Of the 209 PC cases detected, 148 (71%) were csPC. SBx identified 94% of csPC cases, while TBx detected 74% (<em>p</em> ≤ 0.05). SBx also diagnosed significantly more low-grade PCs than TBx (<em>p</em> &lt; 0.001). These findings suggest that relying solely on MRI-TBx may lead to underdiagnosis of csPC. Combining SBx with TBx remains the most effective strategy for early detection of PC in young men undergoing screening. Future research should explore optimization strategies to reduce unnecessary biopsies while maintaining high detection rates for csPC.This trial is registered on the ISRCTN registry as ISRCTN37591328 (<span><span>https://www.isrctn.com/ISRCTN37591328</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>). The study protocol can be accessed at <span><span>https://doi.org/10.1016/j.eururo.2013.05.022</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"51 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144193154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Grant D. Stewart, Angela Godoy, Fiona Farquhar, et al. Abdominal Noncontrast Computed Tomography Scanning to Screen for Kidney Cancer and Other Abdominal Pathology Within Community-based Computed Tomography Screening for Lung Cancer: Results of the Yorkshire Kidney Screening Trial. Eur Urol 2025;87:561–70","authors":"Yi-Qi Chen, Zhi-Bo Zhou, Xue-Qin Bai","doi":"10.1016/j.eururo.2025.05.024","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.024","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"8 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144193144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Chang-kun Mao, Chao-Yang, and Jun-ting Li’s Letter to the Editor re: Marie-Pier St-Laurent, Bernard Bochner, James Catto, et al. Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.026","authors":"Marie-Pier St. Laurent, Sarah P. Psutka","doi":"10.1016/j.eururo.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.02.004","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"4 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144189077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.006","authors":"Gustavo A. Viani, Ana Carolina Hamamura","doi":"10.1016/j.eururo.2025.02.032","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.02.032","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"37 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}